After a complete response letter and a subsequent biologics license application resubmission, denileukin diftitox has been approved by the FDA.
Approval Alert | Denileukin Diftitox in Relapsed/Refractory Cutaneous T-Cell Lymphoma
Advertisement
Advertisement
Trending on CancerNetwork
1
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
